SCOLR Pharma Inc., a specialty pharmaceutical company, said that it has received and shipped initial retail orders for its extended-release nutritional products based on the Company’s proprietary CDT oral drug delivery platform. The shipments represent SCOLR’s first significant direct retail sales of its nutritional products.

Stephen J Turner , SCOLR Pharma’s president and CEO, said, “Shipment of these initial orders marks an important milestone for SCOLR as we continue to focus on growing our nutritional products business into a sustainable source of revenue. We are gratified by the response we have had with retailers and confident that our products are greeted well by consumers.”

Turner said SCOLR intends to provide investors with future updates on its nutritional business activities in conjunction with its quarterly announcements of financial results and in its periodic reports filed with the Securities and Exchange Commission.

SCOLR Pharma, Inc. is focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products.